Combination of ferric ammonium citrate with cytokines involved in apoptosis and insulin secretion of human pancreatic beta cells related to diabetes in thalassemia
- Published
- Accepted
- Received
- Academic Editor
- Gwyn Gould
- Subject Areas
- Biochemistry, Cell Biology, Diabetes and Endocrinology
- Keywords
- Ferric ammonium citrate, Cytokines, Pancreatic beta cell, Thalassemia, Diabetes, Insulin, Apoptosis, Reactive oxygen species, ER stress, Iron overload
- Copyright
- © 2020 Rattanaporn et al.
- Licence
- This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
- Cite this article
- 2020. Combination of ferric ammonium citrate with cytokines involved in apoptosis and insulin secretion of human pancreatic beta cells related to diabetes in thalassemia. PeerJ 8:e9298 https://doi.org/10.7717/peerj.9298
Abstract
Background
Diabetes mellitus (DM) is a common complication found in β-thalassemia patients. The mechanism of DM in β-thalassemia patients is still unclear, but it could be from an iron overload and increase of some cytokines, such as interleukin1-β (IL-1β) and tumor necrosis factor-α (TNF-α). The objective of this study was to study the effect of interaction between ferric ammonium citrate (FAC) and cytokines, IL-1β and TNF-α, on 1.1B4 human pancreatic β-cell line.
Methods
The effect of the combination of FAC and cytokines on cell viability was studied by MTT assay. Insulin secretion was assessed by the enzyme-linked immunosorbent assay (ELISA). The reactive oxygen species (ROS) and cell apoptosis in normal and high glucose condition were determined by flow cytometer. In addition, gene expression of apoptosis, antioxidant; glutathione peroxidase 1 (GPX1) and superoxide dismutase 2 (SOD2), and insulin secretory function were studied by real-time polymerase chain reaction (Real-time PCR).
Results
The findings revealed that FAC exposure resulted in the decrease of cell viability and insulin-release, and the induction of ROS and apoptosis in pancreatic cells. Interestingly, a combination of FAC and cytokines had an additive effect on SOD2 antioxidants’ genes expression and endoplasmic reticulum (ER) stress. In addition, it reduced the insulin secretion genes expression; insulin (INS), glucose kinase (GCK), protein convertase 1 (PSCK1), and protein convertase 2 (PSCK2). Moreover, the highest ROS and the lowest insulin secretion were found in FAC combined with IL-1β and TNF-α in the high-glucose condition of human pancreatic beta cell, which could be involved in the mechanism of DM development in β-thalassemia patients.
Introduction
One of the hereditary blood disorders resulting from a defect in β-globin chain synthesis is β-thalassemia, which is caused by point mutation or, more rarely, deletion of the β-globin gene (Galanello & Origa, 2010). These defects cause an imbalance between α and β-globin chains leading to ineffective erythropoiesis (IE) chronic hemolytic anemia. Extramedullary erythropoiesis is caused by β-thalassemia, which leads to bone deformities and hepatosplenomegaly. Many complications were found such as heart failure, cirrhosis, and endocrine complications including diabetes mellitus (DM) (Weatherall, 2003). The prevalence of DM has been reported by up to 40% in β-thalassemia patients (Ghergherehchi & Habibzadeh, 2015; Li et al., 2014; Liang et al., 2017; Metwalley & El-Saied, 2014).
Patients with β-thalassemia and DM have a higher risk of cardiovascular complications (Pepe et al., 2013). However, the mechanism of DM in β-thalassemia patients is still unclear. Several mechanisms involved in DM development in β-thalassemia patients were reported including insulin resistance, hepatic dysfunction, and insulin deficiency resulting from β-cell damage or apoptosis (Noetzli et al., 2012; Ghergherehchi & Habibzadeh, 2015; Li et al., 2014). However, there is no report linking iron and those mechanisms in β-thalassemia patients.
Pancreatic β-cell damage is caused by many factors such as hyperglycemia, ROS, pharmacological factors, environmental toxicity factors, tumors, chronic pancreatitis, infections, inflammation, and autoimmunity. ROS caused by iron leads to damaged cells via the Fenton reaction. Iron is thought to cause cell death through ROS-dependent and -independent mechanisms (Dixon & Stockwell, 2014; Bogdan et al., 2016). Although the iron metabolism in pancreatic β-cells is still unclear, it is believed that pancreatic islet cells are susceptible to oxidative damage because they express low levels of antioxidants (Tiedge et al., 1997). One study of iron regulation in pancreatic islet cells reported that high expression of divalent metal transporter (DMT1) caused more iron deposits in pancreatic cells than other cells (Andrews, 1999).
In β-thalassemia patients, iron might not be the only factor that causes β-cell damage. Increased levels of inflammatory cytokines have been reported in β-thalassemia patients, especially TNF-α and IL-1β with mean levels 3- and 28-times higher than normal controls, respectively (Wanachiwanawin et al., 1999). These might cause β-cell damage through apoptosis signaling pathways in β-thalassemia patients. In addition, cytokines, especially IL-1β, also have the potential to increase intracellular iron and ROS, which cause apoptosis as has been described in insulin-producing cells (Hansen et al., 2012). Therefore, the increase of both iron and cytokines might be an important mechanism of DM in β-thalassemia patients. Here, the combined effect of iron and cytokines on the human pancreatic β-cell line is examined.
Materials and Methods
Pancreatic cell culture
The human pancreatic β-cell line 1.1B4 was generated by electrofusion of freshly isolated human pancreatic beta cells and the human PANC-1 epithelial cell line. It showed glucose sensitivity and responsiveness to known modulators of insulin secretion (McCluskey et al., 2011). The 1.1B4 cells passage 28 (ECACC Cat. No. 10012801) were routinely cultured in pre-warmed RPMI640 culture medium with L-glutamine containing 11.1 mM glucose (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% v/v fetal bovine serum (Merck, Burlington, MA, USA) and 10 U/ml penicillin and 0.1 g/l streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) at 37 °C in 5%CO2.
1.1B4 cell treatment with FAC, cytokines and high glucose
The 1.1B4 cells were plated on six well plates with or without high glucose condition (22.2 mM glucose) (Vasu et al., 2013) and allowed to attach into cell plates for 24 h. Then, they were treated with different concentrations of FAC (Merck) or IL-1β or TNF-α (Cell Signaling Technology, Danvers, MA, USA) for 12 and 24 h.
Cell viability analysis by MTT assay
MTT assay (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) (Thermo Fisher Scientific, Waltham, MA, USA) was used to compare the effect of FAC, IL-1β, and TNF-α on cell viability. The 1.1B4 cells were plated on 96 well plates and allowed to attach plates for 24 h. After the treatment, the culture medium was removed, and 100 μl of culture medium was added. Then, ten microliters of 12 mM MTT was added and incubated for 4 h at 37 °C. Finally, 85 µL MTT-containing medium and 50 µl DMSO was added to each well and analyzed at 540 nm by a SpectraMax 200 (Molecular Device, San Jose, CA, USA).
Analysis of intracellular ROS by flow cytometer
Intracellular ROS was detected by 2′,7′-Dichlorodihydrofluorescein diacetate (DCFH-DA) (Merck, Kenilworth, NJ, USA); the cells were trypsinized and washed twice with Ca2+ and Mg2+-free Dulbecco’s phosphate buffer saline, then transferred to polypropylene (PP) tube. Then 0.05 mg/mL of DCFH-DA was added into the tube and incubated for 15 min at 37 °C, 5% CO2. The fluorescence signal was detected by a fluorescence-activated cell sorting (FACS) Canto flow cytometer (BD Biosciences, San Jose, CA, USA) and was analyzed by FACSDiva software (BD Biosciences, San Jose, CA, USA).
Analysis of apoptotic cells by flow cytometer
The apoptosis cells were detected using Annexin V: FITC Apoptosis Detection Kit I (BD Biosciences, San Jose, CA, USA). The cells were washed and incubated with fluorescein isothiocyanate (FITC) conjugated Annexin V (AnV) and propidium iodide (PI) at room temperature for 15 min. Fluorescence was detected by a FACSCanto flow cytometer and analyzed with FACSDiva software (BD Biosciences, San Jose, CA, USA).
Gene expression by RT-qPCR
Total RNA was extracted from 1.1B4 cells using TRIzol reagent (Invitrogen, Calsbad, MA, USA). Then, the conversion of 5 µg of total RNA to cDNA using RevertAid kit (Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s instructions, the qPCR was performed using SYBR green. The Select Master Mix for CFX (Applied Biosystem, Foster City, CA, USA) was used for RT-qPCR, through specific primers, and run on CFX96 Touch Real-Time PCR (Bio-Rad, Hercules, CA, USA). The level of target gene expression was normalized against ATCB expression. The mRNA fold change was calculated using the 2−ΔΔCt method, with the values expressed as fold change relative to the untreated control.
Insulin measurement by ELISA
The 1.1B4 cell was treated with FAC alone, cytokine (IL-1β or TNF-α alone), two cytokines (IL-1β + TNF-α), FAC combined with each cytokine (FAC + IL-1β or TNF-α), and FAC combined with both cytokines (FAC + IL-1β + TNF-α) for 24 h. Then, insulin secretion was assayed by ELISA using the human insulin ELISA kit (Merck, Kenilworth, NJ, USA), according to the manufacturer’s protocol.
Statistical analysis
The results were analyzed by one-way and two-way analysis of variance (ANOVA) and presented in mean ± SEM of three independent experiments. The difference in results was considered significant when p < 0.05.
Results
FAC induce ROS production, reduce cell viability, and decrease insulin expression of pancreatic β-cell
The accumulated iron in β-cell islets might promote ROS levels and cell apoptosis leading to a decrease in insulin production. The cellular ROS levels and cytotoxic effects of iron were first examined in pancreatic beta cells. FAC (0.1–15 mM) increased ROS levels in a dose-dependent manner (p < 0.05) (Fig. 1A). In addition, FAC induced pancreatic cell apoptosis and reduced cell viability in a dose- and time-dependent manner (Figs. 1B–1C and 1G). The highest ROS (MFI 1,375 ± 64.26) and apoptosis (40%) were found in 15 mM FAC-treated cells at 24 h (Figs. 1A and 1B). Expression of apoptotic regulatory proteins include BAX, BCL2 and STAT1 were assessed to study the effect of FAC on β-cell apoptosis. In the 1.1B4 cells treated with 8 mM FAC the BAX were up-regulated at 12 h and down-regulated at 24 h while BCL2 was down-regulated at 12 and 24 h (Figs. 1D–1F). The lowest cell viability (40%, p < 0.001) was found in cells treated with 10 and 15 mM FAC for 24 h (Fig. 1G).
Insulin expression and secretion were assessed to study the effect of FAC on β-cell function. In the 1.1B4 cells treated with 8 mM FAC the insulin (INS) expression and insulin level decreased in a time-dependent manner (Figs. 1H and 1I).
Combination of FAC and cytokines induce ROS production, apoptosis, and reduces insulin expression of pancreatic β-cells
Cytokine activates the production of ROS and reduction of insulin secretion which lead to diabetes. The effect of FAC combined with cytokines on pancreatic β-cells was observed. Cells were treated with IL-1β alone, TNF-α alone, IL-1β combined with TNF-α, FAC alone, and FAC combined with IL-1β, FAC combined with TNF-α, and FAC combined with IL-1β and TNF-α for 24 h. The results showed that ROS and percentage of apoptosis increased but had not significantly different compared between FAC with cytokines and FAC alone (Figs. 2A and 2B). Insulin secretion and INS expression was reduced in FAC combined with IL-1β or TNF-α compared with FAC alone (Figs. 2C and 2D).
The effect of 22.2 mM high glucose was also investigated in 1.1B4 cells, cell viability of pancreatic cell treated with cytokines with FAC was lower than in a normal glucose condition. The lowest cell viability was found in FAC combined with IL-1β and TNF-α in a high-glucose condition (Fig. 3A). In addition, the highest ROS was found in FAC combined with IL-1β and TNF-α in the high-glucose condition (Fig. 3B). Apoptosis of pancreatic cells in the high-glucose condition was higher than in the normal glucose condition. Interestingly, the highest apoptosis (Fig. 3C), lowest insulin secretion (Fig. 3D) and lowest INS expression were found in FAC combined with IL-1β and TNF-α in the high-glucose condition (Fig. 3E).
FAC combined with IL-1β and TNF-α decrease secretory function genes through antioxidant defense, apoptosis, and ER stress
From these results showed that iron (FAC) and cytokines reduce insulin secretion capacity, this evidence was examined by measuring the expression of genes involved in antioxidant defense, apoptosis pathways, ER stress, and secretory function (Fig. 4). Two important antioxidant genes in the pancreas, including superoxide dismutase 2 (SOD2) and glutathione peroxidase 1 (GPX.1) were measured. The results showed that the highest SOD2 expression was found in FAC combined with TNF-α alone and FAC combined with IL-1β and TNF-α (Fig. 4A). In addition, apoptosis-related genes, including B-cell lymphoma 2 (BCL2), Nuclear factor-κB (NFκB), and signal transducer and activator of transcription 1 (STAT1) were studied. The results showed that the expression of BCL2, NFκB, and STAT1 was decreased (Figs. 4C–4E). Gene expressions of Heat Shock Protein Family A (Hsp70) Member 4 (HSPA4) and Heat Shock Protein Family A (Hsp70) Member 5 (HSPSA5), ER stress marker genes, were analyzed. The highest gene expression of HSPA4 was shown in FAC combined with both cytokines. However, the gene expression of HSPA5 was decreased (Figs. 4F and 4G). Moreover, insulin-secretion related genes including glucose kinase (GCK), proprotein convertase subtilisin/kexin type 1 (PCSK1), and proprotein convertase subtilisin/kexin type 2 (PCSK2) were determined. The expressions of these genes were decreased more than two times in FAC treated alone and in combination with cytokines (Figs. 4H–4J).
Discussion
DM is commonly found in β-thalassemia patients. The overload of iron and increased of cytokines may affect the β-cell function and insulin secretion capacity, which lead to DM (Wanachiwanawin et al., 1999). However, the mechanism of DM in thalassemia is still unclear. The purpose of this research is to study the effect of FAC combined with cytokines IL-1β and TNF-α on 1.1B4 in the human pancreatic islet cell line.
Firstly, we found that iron exposure resulted in a reduction of cell viability, induction of ROS, and increasing of apoptosis in a dose-dependent manner in 1.1B4 cells that have been previously reported in other types of cell line such as HH4, human hematopoietic cells/mesenchymal cells, MC3T3-E1 cells, and MG-63 cells through different mechanisms (Li et al., 2016; Lu et al., 2013; Doyard et al., 2012; Yang et al., 2017; Ke et al., 2017). Many reports have been demonstrated that iron overload lead to increasing intracellular ROS and caused cell damage, which is concomitant with our results. Moreover, our results showed the reduction of INS expression and insulin secretion that might be affected by ROS induced by FAC, which finally cause β-cell damage. FAC was previously used to induce the excess intracellular iron and caused increasing of ROS affected insulin secretion in Rat insulinoma pancreatic β-cells (RINm5F) as a model of pancreatic iron overload in β-thalassemia patients (Koonyosying et al., 2019).
The toxic effects of cytokines was studied but the mechanism or pathway underlying those effects in pancreatic β-cell is still unclear. Numerous studies whose findings reported that short-term treatment with cytokines such as IL-1β, TNF-α, and interferon γ (IFN-γ), alone or in combination could induce apoptosis of islet cells and dysfunction of pancreatic β-cells to release insulin (Vasu et al., 2014; Wang, Guan & Yang, 2010), are concomitant with our results.
Interestingly, β-thalassemia patients with iron overloading had high levels of these cytokines and high percentage of apoptosis. The iron and cytokines-induced apoptosis might be the cause of β-cell dysfunction and DM development in these patients. From our results, FAC combined with IL-1β and TNF-α had an additive effect on reducing INS expression, inducing SOD2 antioxidants’ genes expression and activating endoplasmic reticulum (ER) stress. The increasing of ROS in FAC combined with IL-1β and TNF-α induced the expression of antioxidant SOD2 have been reported (Wang et al., 2018). In addition, the induction of SOD2 expression by cytokines was reported (Vasu et al., 2014). Moreover, the result revealed that the HSPA4 heat shock 70 kDa protein 4 genes responded to the activation of oxidative stress, protein-folding, and secretion demands that can be found in hyperglycemia (Berchtold et al., 2016). Jacob and co-workers found that 100 pg/ml of IL-1β induced divalent metal transporter 1 (DMT1) expression and caused increasing of ROS and activating apoptosis pathway in pancreatic islets cells (Hansen et al., 2012). This information is not consistent with our results that ROS and apoptosis in FAC combined with IL-1β and/or TNF-α were not significantly different from FAC treated alone.
Iron-induced ROS can activate ferroptosis which might be the possible mechanism of pancreatic β-cell damage in our study. It is a non-apoptosis cell death is induced by the small molecule or condition that inhibits glutathione biosynthesis or the cellular glutathione-dependent antioxidant enzyme glutathione peroxidase 4 (GPX4) and results in an accumulation of ROS (Cao & Dixon, 2016; Xie et al., 2016).
Experiments conducted with high glucose concentrations shows significant apoptotic death compared to normal medium in untreated cells however no change in cell count and ROS, because high glucose could activate apoptosis signaling pathway and down-regulation of anti-apoptotic proteins BCL2, MAPK8, and MAPK10 (Vasu et al., 2013). However, only high glucose had less affect to cell count and level of ROS but when combine high glucose with FAC, and cytokines could lead to increase level of ROS. Hyperglycemic condition in the combination of FAC and cytokines induce production of ROS and lead to apoptosis and cause reducing of insulin in 1.1B4 cells that might be resulting from the down regulation of INS and other genes involved in insulin secretion, including GCK, PSCK1, and PSCK2 (Vasu et al., 2014; Kooptiwut et al., 2005; Jonas et al., 2009; Laybutt et al., 2002). This might be due to the interference of high glucose that reduces the PDX1, an important gene involved in the secretory function (Sachdeva et al., 2009). The effect of cytokines on insulin production in hyperglycemia was found (Zhang & Kim, 1995; Kiely et al., 2007). Moreover, it was found that glucose toxicity induced ROS production and activated the apoptosis signaling pathway (Robertson, 2004). This information is concomitant with our study that the highest ROS, the lowest INS expression, and insulin secretion were found in FAC combined with IL-1β and TNF-α in high glucose level. This results could be supported the mechanism of insulin dependent or DM development in β-thalassemia patients who had iron overload and high level of cytokines IL-1β or TNF-α.
However, this study was performed only in human pancreatic β-cell line as a model which no direct measurement in humans and external validation but our previous data suggests that in β-thalassemia/HbE patients with diabetes had high level of ROS, low level of glutathione, reduced the β-cell function (HOMAB) and insulin level decreased (P. Rattanaporn, 2019, unpublished data).
Conclusions
This study suggests that FAC combined with cytokines, IL-1β and TNF-α in high glucose condition could increase ROS production, ER stress and apoptosis induction. However, they reduce insulin secretion in human pancreatic β-cell lines. This information could be benefit for understanding the mechanism on development of DM in thalassemia patient.